MACH7 TECHNOLOGIES LIMITED — Interim / Quarterly Report 2026

Oct 30, 2025

==> picture [374 x 122] intentionally omitted <==

Q1 FY26 Result Presentation

31 October 2025

Mach7 Technologies | ASX: M7T

==> picture [287 x 89] intentionally omitted <==

Mach7 Technologies delivers advanced image data management and diagnostic viewing solutions to healthcare organisations worldwide.

Q1 FY26 Financial Highlights

Reset quarter as we begin to execute a full commercial transformation.

==> picture [37 x 172] intentionally omitted <==

==> picture [602 x 174] intentionally omitted <==

----- Start of picture text -----

VHA NTP
29.6M 23.5M
A$ A$
initial go-live
CARR [1] ARR [2] Run Rate
Phase 1 limited
-A$0.4M on 30 Jun 2025 +A$0.1M on 30 June 2025
go-live
In constant currency In constant currency
----- End of picture text -----

==> picture [37 x 172] intentionally omitted <==

==> picture [37 x 172] intentionally omitted <==

M A$18.9 2.6M A$ Closing Cash Q1 FY26 Sales Orders A$23.1M at 30 Jun 2025 Q1 FY25: A$2.3M TCV[3] Strong financial position with no debt

==> picture [36 x 172] intentionally omitted <==

Lower staff costs Q1 FY26: -18% on pcp Right size leadership team, operational efficiencies

1. CARR: Contracted Annual Recurring Revenue; 2. Annual Recurring Revenue (ARR) Run Rate is calculated by annualising the revenue earned from Subscription and Maintenance and Support fees; 3. Total Contract Value (TCV). Q1 FY25 sales orders are in constant currency.

3

1

2

3

4

Strategic directions

From archive to architecture.

==> picture [298 x 363] intentionally omitted <==

----- Start of picture text -----

49%
58%
32%
32%
10%
10%
58%
58%
----- End of picture text -----

The imaging industry is undergoing rapid change, costs are soaring, talent is scarce, and data silos persist. Agentic AI is emerging as the catalyst for efficiency, innovation, and opportunities for Mach7 to capture market leadership.

Mach7’s mission is simple: connecting images, people, and insights, advancing care today and activating the power of AI now.

Building the foundation for intelligent imaging ecosystems, empowering customers to deploy AI and embedding intelligence across our platform to deliver unmatched interoperability, scalability, and value.

Dynamic Operating Model aligning strategy, structure, technology, and talent. A performance culture built on accountability, agility & results.

4

Market opportunity

Uniquely positioned to capitalise on VNA architecture, AI-ready interoperability and price-to-performance advantage.

==> picture [703 x 247] intentionally omitted <==

----- Start of picture text -----

Healthcare
Enterprise AI in medical Rapid growth in
experiencing
imaging market imaging is radiology,
data explosion
projected to fastest growing cardiology,
driving demand
double to $4.1bn segment oncology and
for unified
by 2030 [1] teleradiology
platforms
----- End of picture text -----

==> picture [146 x 432] intentionally omitted <==

1. Source: MarketsandMarkets.com

5

Product and innovation roadmap

==> picture [64 x 64] intentionally omitted <==

==> picture [61 x 61] intentionally omitted <==

New architecture launch

eUnity expansion

Enable Agentic AI through open Evolution of eUnity into a full teleAPIs that unify data flow, imaging platform, uniting radiology, empowering providers to deploy advanced visualisation, and pathology AI & achieve data independence. for real-time collaboration and distributed diagnostics.

==> picture [55 x 47] intentionally omitted <==

Additional capabilities

Embedding telemetry and AI-driven optimisation across deployments to enable predictive maintenance, capacity forecasting & more.

==> picture [960 x 157] intentionally omitted <==

6

1

2

3

4

Asia: from quiet outpost to strategic growth engine

Establishing a low-cost innovation hub.

Capitalising on VNA growth in Asia and the Middle East leveraging our impending CE Mark and regional position for capital sales in enterprise and government opportunities globally.

Establish strategic beachhead for expansion and innovation, enabling AI readiness, interoperability, and platform innovation.

Founder Ravi Krishnan re-engaged, bringing renewed focus, innovation energy, and deep regional insight to accelerate growth.

==> picture [327 x 352] intentionally omitted <==

----- Start of picture text -----

49%
58%
32%
32%
10%
10%
58%
58%
----- End of picture text -----

7

Operating model and framework

==> picture [39 x 40] intentionally omitted <==

==> picture [40 x 41] intentionally omitted <==

==> picture [40 x 41] intentionally omitted <==

==> picture [40 x 40] intentionally omitted <==

Purpose and Value Agenda

Purpose anchors decisions to improve patient care; value agenda aligns resources to customer outcomes and monetisation models.

Organisational Structure

Structure empowers accountable mission teams supported by AI-enabled execution, restructured functions, and global delivery hubs.

Leadership and Governance

Leadership expectations drive ownership and rapid decisions; governance ensures alignment through regular executive reviews.

Technology and Security

Technology adoption accelerates automation and AI use; cybersecurity measures protect data integrity and compliance.

==> picture [473 x 379] intentionally omitted <==

Source: McKinsey performance framework.

8

Commercial transformation and innovation

Driving profitable growth through innovation, execution and accountability.

• Comprehensive leadership refresh – Realigned leadership to boost execution, innovation and sustainable growth with sharper focus and accountability.

• Commercial transformation – Overhaul of sales, customer success and product teams to align with customer value and growth goals.

• Innovation and operational strategy – Chief Innovation Officer (CIO) unifying product and development, Asia and North America to accelerate innovation.

• Cost efficient global hubs – Expanding costefficient hubs in Waterloo and Malaysia.

==> picture [320 x 335] intentionally omitted <==

----- Start of picture text -----

49% 58%
32%
32%
10%
10%
58%
58%
----- End of picture text -----

9

Transforming our customer engagement

Flight Crew - revitalising how Mach7 serves its customers and partners.

==> picture [40 x 41] intentionally omitted <==

One multi-disciplinary customer designated team

Led by Advocate for Customer Experience (ACE) Clear accountability improves support response time Single point of accountability reduces time and improves Delivers consistent Mach7 experience project alignment Stronger relationships provides greater continuity

==> picture [39 x 41] intentionally omitted <==

Drives Mach7 Loop

==> picture [339 x 370] intentionally omitted <==

10

Mach7 CLIMBS culture code

Culture is the execution engine of our strategy.

==> picture [40 x 331] intentionally omitted <==

C ustomer First Principle L earn and Grow I nnovate for Impact M inimise complexity and move B uild with ownership

S ell and grow together

==> picture [355 x 382] intentionally omitted <==

11

Outlook

==> picture [355 x 382] intentionally omitted <==

Mach7 is well positioned to execute its strategic ambitions with a refreshed leadership team driving technical, cultural, and operational changes.

We strive to reshape how imaging data powers healthcare and to translate innovation into financial performance.

Financial discipline remains central with a focus on operating cashflows and accelerating towards profitability.

While it remains on foot, Mach7 has paused activity in the onmarket share buy-back program pending completion of the strategic review.

More details on the growth strategy including FY26 guidance will be provided at the 2025 AGM.

12

==> picture [376 x 118] intentionally omitted <==

Contact Us

Investor Relations, Mach7 Françoise Dixon +61 (0) 412 292 977 ir@mach7t.com

Registered Office: Suite 2, Level 11, 385 Bourke St, Melbourne, VIC 3000

This document was authorised for release to the ASX by Teri Thomas, Managing Director and Chief Executive Officer

Mach7 Technologies

Disclaimer “Forward looking” statements

Summary of information: This presentation contains general and background information about Mach7 Technologies Limited (“M7T”) activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision. This presentation is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or under any other law. The presentation does not purport to contain all the information that a prospective investor may require in assessing a possible investment in M7T nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). The information provided is in summary form, has not been independently verified, and should not be considered to be comprehensive or complete. It should be read solely in conjunction with the oral briefing provided by M7T and all other documents provided to you by M7T. The information in this presentation remains subject to change without notice. M7T is not responsible for providing updated information and assumes no responsibility to do so.

Not financial product advice: This financial information provided in this presentation is for information purposes only. The information contained in this presentation is of a general nature only and is not a financial product, investment advice or a recommendation to acquire M7T securities and has been prepared without taking into account the objectives, financial situation or needs of any person or entity. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. M7T is not licensed to provide financial product advice in respect of its securities or and other financial products. Cooling off rights do not apply to the acquisition of M7T securities. M7T assumes that the recipient is capable of making its own independent assessment, without reliance on this document, of the information and potential investment and will conduct its own investigation.

Disclaimer: M7T and its related bodies corporate and each of their respective directors, agents, officers, employees and advisors expressly disclaim, to the maximum extent permitted by the law, all abilities (however, caused, including negligence) in respect of, make no representations regarding, and take no responsibility for, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this presentation does not constitute, and shall not be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of M7T.

Future performance: This presentation contains certain forward-looking statements and opinions. The forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forwardlooking statements, including projections, forecasts and estimates, are provided as a general guide only and should not be relied on as an indication or guarantee of future performance and involve known and unknown risks, uncertainties and other factors, many of which are outside the control of M7T. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

Risks: An investment in M7T securities is subject to investment and other known and unknown risks, some of which are beyond the control of M7T. You should have regard to the ‘Key Risks’ section of this presentation which outlines some of these risks.

Not an offer: This presentation is not, and should not be considered as, an offer or an invitation to acquire securities in M7T or any other financial products and neither this document nor any of its contents will form the basis of any contract or commitment. This presentation is not a prospectus. Offers of securities in M7T will only be made in places which, or to persons to whom it would be lawful to make such offers. This presentation must not be disclosed to any other party and does not carry any right of publication. Neither this presentation nor any of its contents may be reproduced or used for any other purpose without the prior written consent of M7T.

No distribution in the US: This presentation is not an offer of securities for sale in the United States. Any securities to be issued by M7T have not been and will not be registered under the US Securities Act of 1933, as amended (the “US Securities Act”) and may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act. No public offer of the securities is being made in the United States and the information contained herein does not constitute an offer of securities for sale in the United States. This presentation is not for distribution directly or indirectly in or into the United States or to US persons.

Monetary values: Unless otherwise stated, all dollar values are in Australian dollars (AUD$). The information in this presentation remains subject to change without notice.

Sophisticated and professional investor: By attending this presentation, you present and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document as defined in the Corporation Act 2001 (Cth) (“Corporation Act”)) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are in the United States, you are a qualified institutional buyer (as defined under Rule 144A Under the U.S. Securities Act; (iii) if you are outside Australia and the United States, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this presentation and any copies and do not provide this presentation to any other person.

No distribution: Distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable security laws.

14